A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Principal Investigator
Donna E. HoggeOverview
Body Locations and Systems
LeukemiaDisorders and Conditions
ClinicalTrials.gov#
NCT02039726Status
RecruitingStudy Start/End
Sep 19, 2014 to Jun 7, 2019Locations
Vancouver General HospitalName/Title
Jill Clark, Research NursePhone
604-875-4111 ext.62887Email Address
jclark@bccancer.bc.caPurpose of Study
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.